CJC-1295 with DAC
Also: CJC-1295 DAC, CJC-1295 (DAC), CJC-1295 with Drug Affinity Complex, DAC:GRF, long-acting GHRH(1-29) analog
This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more
CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) discussed in the research literature as a laboratory compound. It pairs a modified GHRH(1-29) peptide sequence with a Drug Affinity Complex (DAC) moiety that sources describe as binding to circulating albumin, a property those sources report as extending the molecule's reported duration of action. It is examined in preclinical and mechanistic contexts as a tool for studying GHRH-receptor signaling and growth hormone release. The available evidence is limited and largely preclinical, terminology varies between sources, and any claims should be interpreted cautiously and verified editorially.
Mechanism as described in the literature
CJC-1295 with DAC is described in the research literature as a synthetic analog of growth hormone-releasing hormone (GHRH), built on a modified GHRH(1-29) sequence carrying amino-acid substitutions reported to slow enzymatic breakdown. As a GHRH-receptor agonist, it is described in preclinical and mechanistic models as acting on somatotroph cells of the anterior pituitary, which release growth hormone in a manner that some models describe as secondarily influencing insulin-like growth factor 1 (IGF-1). These mechanisms are characterized primarily in vitro and in animal models, and translation to other contexts is not established.
The Drug Affinity Complex (DAC) component is a chemical moiety described as forming a bond with circulating serum albumin, which sources report as extending the molecule's half-life relative to non-DAC GHRH analogs. This reported distinction is the main feature separating it from related compounds sometimes labeled "CJC-1295 without DAC" or "modified GRF(1-29)." Because naming conventions differ across sources, the identity of any given material requires editorial and source verification.
Research areas
- GHRH-receptor signaling and pituitary growth hormone release (preclinical/mechanistic)
- Pharmacokinetics of albumin-binding (DAC) half-life extension as described in the literature
- Growth hormone / IGF-1 axis regulation in animal models
- Comparative behavior of DAC versus non-DAC GHRH analogs
- Analytical characterization, identity confirmation, and documentation/testing visibility of synthetic peptide materials
Documentation notes
References
Frequently asked questions
What is CJC-1295 with DAC?+
It is a synthetic analog of growth hormone-releasing hormone (GHRH) discussed in the research literature, combining a modified GHRH(1-29) peptide with a Drug Affinity Complex (DAC) moiety that sources report binds albumin and is associated with a longer reported duration of action. It is handled as a research-use-only compound, and the existing record supports no safety or efficacy conclusions.
How is the DAC version different from CJC-1295 without DAC?+
Sources describe the DAC moiety as binding to serum albumin, a property those sources report as extending the molecule's half-life, whereas non-DAC versions (sometimes labeled modified GRF(1-29)) are described as acting over a shorter window. Naming is inconsistent across sources, so the identity of any specific material should be verified editorially.
Is there strong human evidence for CJC-1295 with DAC?+
No. The available literature is largely preclinical and mechanistic, and human data are limited. Findings should be interpreted cautiously given study-design and translation limitations, and no therapeutic conclusions are supported.